Next Article in Journal
PD-L1/PD-1 Expression in the Treatment of Oral Squamous Cell Carcinoma and Oral Potentially Malignant Disorders: An Overview of Reviews
Previous Article in Journal
The Role of the Gut–Biliary–Liver Axis in Primary Hepatobiliary Liver Cancers: From Molecular Insights to Clinical Applications
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JPM
Volume 15
Issue 4
10.3390/jpm15040125
jpm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Presepsin: An Emerging Biomarker in the Management of Cardiometabolic Disorders

by
Dimitrios Kouroupis
1,
Ioanna Zografou
1,
Panagiotis Doukelis
1,
Dimitrios Patoulias
1,
Djordje S. Popovic
2,
Paschalis Karakasis
3,
Athina Pyrpasopoulou
1,
Konstantinos Stavropoulos
1,
Christodoulos Papadopoulos
4,
Olga Giouleme
5,
Kalliopi Kotsa
6,
Michael Doumas
1 and
Theocharis Koufakis
1,*
1
Second Propedeutic Department of Internal Medicine, Hippokration General Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece
2
Clinic for Endocrinology, Diabetes and Metabolic Disorders, Clinical Centre of Vojvodina, Medical Faculty, University of Novi Sad, 21000 Novi Sad, Serbia
3
Second Department of Cardiology, Aristotle University of Thessaloniki, Hippokration General Hospital, 54642 Thessaloniki, Greece
4
Third Department of Cardiology, Hippokration General Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece
5
Second Propedeutic Department of Internal Medicine, Hippokration General Hospital, Gastroenterology and Hepatology Division, Medical School, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece
6
Division of Endocrinology and Metabolism and Diabetes Centre, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, 54636 Thessaloniki, Greece
*
Author to whom correspondence should be addressed.
J. Pers. Med. 2025, 15(4), 125; https://doi.org/10.3390/jpm15040125
Submission received: 12 February 2025 / Revised: 18 March 2025 / Accepted: 23 March 2025 / Published: 25 March 2025
(This article belongs to the Section Disease Biomarker)
Browse Figure
Versions Notes

Abstract

Background/Objectives: Systemic and tissue inflammation play a crucial role in the pathophysiology of cardiometabolic disorders. Presepsin is a newly discovered marker of acute phase inflammation that is produced by monocytes or macrophages in response to bacterial infection and is a soluble fraction of the lipopolysaccharide (LPS) receptor. LPS is an endotoxin that, through the breakdown of the intestinal barrier, penetrates the systemic circulation and is an important bacterial mediator in the pathogenesis of sepsis and septic shock. Methods: A narrative review of the existing literature. Results: A growing body of evidence demonstrates that intestinal dysbiosis is involved in the pathogenesis of diabetes mellitus (DM) and cardiovascular (CV) disease, leading to increased circulating LPS concentrations in people with cardiometabolic disorders, even in the absence of infection. These data provide the theoretical background for a link between presepsin, DM, and CV pathology. Preliminary studies suggest that presepsin levels are downregulated in patients with well-controlled type 2 DM and correlate with continuous glucose monitoring metrics in infection-free individuals with type 1 DM. However, prospective data on the association between presepsin and the risk of diabetic complications are currently lacking. Presepsin has also been found to be elevated in infection-free individuals with myocardial infarction, heart failure, and myocarditis compared to controls and has been shown to correlate with mortality risk in subjects at high CV risk. Conclusions: The clinical utility of presepsin in the monitoring of patients with cardiometabolic disorders warrants further investigation by future studies.
Keywords: presepsin; diabetes; inflammation; biomarker; innate immune system; cardiovascular disease presepsin; diabetes; inflammation; biomarker; innate immune system; cardiovascular disease

Share and Cite

MDPI and ACS Style

Kouroupis, D.; Zografou, I.; Doukelis, P.; Patoulias, D.; Popovic, D.S.; Karakasis, P.; Pyrpasopoulou, A.; Stavropoulos, K.; Papadopoulos, C.; Giouleme, O.; et al. Presepsin: An Emerging Biomarker in the Management of Cardiometabolic Disorders. J. Pers. Med. 2025, 15, 125. https://doi.org/10.3390/jpm15040125

AMA Style

Kouroupis D, Zografou I, Doukelis P, Patoulias D, Popovic DS, Karakasis P, Pyrpasopoulou A, Stavropoulos K, Papadopoulos C, Giouleme O, et al. Presepsin: An Emerging Biomarker in the Management of Cardiometabolic Disorders. Journal of Personalized Medicine. 2025; 15(4):125. https://doi.org/10.3390/jpm15040125

Chicago/Turabian Style

Kouroupis, Dimitrios, Ioanna Zografou, Panagiotis Doukelis, Dimitrios Patoulias, Djordje S. Popovic, Paschalis Karakasis, Athina Pyrpasopoulou, Konstantinos Stavropoulos, Christodoulos Papadopoulos, Olga Giouleme, and et al. 2025. "Presepsin: An Emerging Biomarker in the Management of Cardiometabolic Disorders" Journal of Personalized Medicine 15, no. 4: 125. https://doi.org/10.3390/jpm15040125

APA Style

Kouroupis, D., Zografou, I., Doukelis, P., Patoulias, D., Popovic, D. S., Karakasis, P., Pyrpasopoulou, A., Stavropoulos, K., Papadopoulos, C., Giouleme, O., Kotsa, K., Doumas, M., & Koufakis, T. (2025). Presepsin: An Emerging Biomarker in the Management of Cardiometabolic Disorders. Journal of Personalized Medicine, 15(4), 125. https://doi.org/10.3390/jpm15040125

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop